Edition:
United States

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

10.00USD
17 Aug 2018
Change (% chg)

$0.36 (+3.73%)
Prev Close
$9.64
Open
$10.00
Day's High
$10.00
Day's Low
$10.00
Volume
194
Avg. Vol
588
52-wk High
$30.48
52-wk Low
$9.64

Latest Key Developments (Source: Significant Developments)

BVF Partners Reports 20.2 Pct Stake In Erytech Pharma SA As Of July 16
Thursday, 19 Jul 2018 06:22am EDT 

July 19 (Reuters) - BVF Partners LP::BVF PARTNERS LP REPORTS 20.2 PERCENT STAKE IN ERYTECH PHARMA SA AS OF JULY 16 - SEC FILING.BVF PARTNERS LP PURCHASED ERYTECH PHARMA SA SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Oncodesign Concludes A Partnership With Erytech In Oncology
Tuesday, 27 Mar 2018 12:00pm EDT 

March 27 (Reuters) - ONCODESIGN SA ::ONCODESIGN CONCLUDES A LONG TERM SERVICE-BASED PARTNERSHIP WITH ERYTECH IN ONCOLOGY.PARTNERSHIP AIMS TO ESTABLISH POTENTIAL OF ERYASPASE AND ERYMETHIONASE IN TREATMENT OF SOLID TUMORS.  Full Article

Erytech FY Net Loss Widens To 33.5 Million Euros
Tuesday, 13 Mar 2018 03:16am EDT 

March 13 (Reuters) - Erytech ::REPORTED ON MONDAY FY NET LOSS 33.5 MILLION EUROS, COMPARED TO 21.9 MILLION EUROS IN 2016.CASH POSITION OF 185.5 MILLION EUROS AT YEAR-END.FY TOTAL OPERATING LOSS 30.9 MILLION EUROS VS LOSS 22.4 MILLION EUROS YR AGO .  Full Article

Erytech Pharma Selects Triple Negative Breast Cancer As Next Indication For Eryaspase​
Tuesday, 13 Feb 2018 01:40am EST 

Feb 13 (Reuters) - ERYTECH PHARMA SA ::‍ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE​.‍SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018​.  Full Article

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
Friday, 8 Dec 2017 01:52am EST 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.  Full Article

Erytech Pharma SA ADS debut about 14.7 pct above IPO price
Friday, 10 Nov 2017 09:55am EST 

Nov 10 (Reuters) - :Erytech Pharma SA ADS open at $26.68 in debut on the NASDAQ versus IPO price of $23.26 per ADS‍​‍​​.  Full Article

Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​
Friday, 10 Nov 2017 08:08am EST 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​.‍GLOBAL OFFERING COMPRISING AN OFFER OF 4.7 MILLION ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES​.IN ‍UNITED STATES, OFFERING PRICE OF $23.26 PER ADS​.‍PRIVATE PLACEMENT IN EUROPE (INCL. FRANCE) AND OTHER COUNTRIES (EXCLUDING. US AND CANADA) OF 0.7 MILLION ORDINARY SHARES AT OFFERING PRICE OF EUR 20 PER SHARE.‍LISTING ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL "ERYP"​.‍GLOBAL OFFERING FOR TOTAL GROSS PROCEEDS OF ABOUT $125 MILLION BEFORE DEDUCTING UNDERWRITING COMMISSIONS AND ESTIMATED EXPENSES PAYABLE BY CO​.‍CLOSING OF GLOBAL OFFERING EXPECTED ON OR ABOUT NOV 14, 2017​.‍FOLLOWING CLOSING COMPANY WILL HAVE ISSUED 5,374,033 ORDINARY SHARES (INCL. ADSS)​.  Full Article

Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​
Friday, 10 Nov 2017 02:18am EST 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS.SUSPENSION TO ALLOW FOR CONFIRMATION OF ALLOCATIONS TO INVESTORS & CO'S ADSS BEGINNING TRADING ON NASDAQ GLOBAL SELECT MARKET .‍SUSPENSION EFFECTIVE UNTIL A NEW COMMUNICATION IS RELEASED BY COMPANY​.‍TRADING ON REGULATED MARKET OF EURONEXT PARIS EXPECTED TO RESUME NOV 10, 2017 ABOUT 4:00 PM (CET)​.  Full Article

Erytech Pharma 9M net loss widens to 20.8 million euros
Tuesday, 7 Nov 2017 01:45am EST 

7 Nov(Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 80.3 MLN ON SEPT 30, VS 88.5 MLN ON JUNE 30.FINANCIAL RESULTS ARE IN LINE WITH STRATEGY FOR 2017.  Full Article

Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs
Monday, 6 Nov 2017 01:36pm EST 

Nov 6 (Reuters) - Erytech Pharma SA :Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing.Erytech Pharma SA says U.S. IPO price is expected to be between $23.00 and $24.00 per ADS.  Full Article

BRIEF-Erytech To Present Results From Phase I Trial Of Eryaspase In All And New Pre Clinical Data At Aacr 2018

* ERYTECH TO PRESENT RESULTS FROM PHASE I TRIAL OF ERYASPASE IN ALL AND NEW PRE-CLINICAL DATA AT AACR 2018 Source text for Eikon: Further company coverage: